Diferencia entre revisiones de «Erythromycin»

(Replace manual dosing with dynamic SMW tables (Adult + Pediatric))
(Restore original dosing content alongside dynamic SMW tables)
Línea 5: Línea 5:


==Adult Dosing==
==Adult Dosing==
*250-500mg PO q6h
===Pre-endoscopy===
*3mg/kg IV over 20-30min, 30-90min prior to endoscopy
**Achieves endoscopy conditions equal to lavage<ref>Pateron D, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011; 57(6):582-589.</ref>
===Indications by Disease===
===Indications by Disease===
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Adult]]
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Dose=Dose
|?Has Context=Context
|?Has Context=Context
|format=table
|format=table
|limit=50
|limit=50
|mainlabel=-
|mainlabel=-
|headers=show
|headers=show
|sort=Treats disease
|sort=Treats disease
}}
}}


==Pediatric Dosing==
==Pediatric Dosing==
*Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr 
*Severe infection: 60-100 mg/kg/day PO divided q6-8hr
===Indications by Disease===
===Indications by Disease===
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Pediatric]]
{{#ask: [[Has DrugName::Erythromycin]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Dose=Dose
|?Has Context=Context
|?Has Context=Context
|format=table
|format=table
|limit=50
|limit=50
|mainlabel=-
|mainlabel=-
|headers=show
|headers=show
|sort=Treats disease
|sort=Treats disease
}}
}}


Revisión del 02:38 20 mar 2026

General

  • Type: Macrolide
  • Dosage Forms: PO, IV, topical
  • Common Trade Names:

Adult Dosing

  • 250-500mg PO q6h

Pre-endoscopy

  • 3mg/kg IV over 20-30min, 30-90min prior to endoscopy
    • Achieves endoscopy conditions equal to lavage[1]


Indications by Disease

DiseaseDoseContext
Acute diarrhea500mg PO BID x 5 daysCampylobacter
Bacterial conjunctivitisapplied to the conjunctiva q6hrs for 7 daysBacterial Conjunctivitis, Topical
Corneal abrasionointment qid x 3-5dNo Contact Lens
Lymphogranuloma venereum500mg PO QID x 21 daysAlternative
Pertussis500mg QID x7 daysAdults
Undifferentiated upper gastrointestinal bleeding3mg/kg IV over 20-30min, 30-90min prior to endoscopy; Achieves endoscopy conditions equal to lavage'"`UNIQ--ref-0000001F-QINU`"'Pre-endoscopy

Pediatric Dosing

  • Mild-moderate infections: 30-50 mg/kg/day PO divided q6-8hr
  • Severe infection: 60-100 mg/kg/day PO divided q6-8hr


Indications by Disease

DiseaseDoseContext
Acute diarrhea10mg/kg PO QID x 5 days (max 500mg/dose)Pediatric Campylobacter
Bacterial conjunctivitis0.5% ophthalmic ointment applied q6hrs x 7 daysPediatric
Corneal abrasion0.5% ointment applied QID x 3-5 daysPediatric
Diphtheria40mg/kg/day (max 2g/day)
Neonatal conjunctivitis0.5% ointment topical x1Prophylaxis at birth
Neonatal conjunctivitis50mg/kg PO daily in 4 divided doses x 14 daysChlamydial conjunctivitis
Pertussis10mg/kg PO QID x 14 days (max 2g/day)>1 month old
Pneumonia (peds)10mg/kg q6hrs1-3 month afebrile pneumonitis

Special Populations

Contraindications

  • Allergy to class/drug
  • QT prolongation

Adverse Reactions

Serious

  • Torsades, ventricular dysrhythmias
  • Pseudomembranous colitis
  • Hypertrophic pyloric stenosis
  • Seizures

Common

  • nausea/vomiting
  • diarrhea
  • urticaria
  • transaminitis
  • urticarial rash

Pharmacology

  • Half-life: 2 hours
  • Metabolism: Liver
  • Excretion: Bile/Renal
  • Mechanism of Action: Binds to 50S ribosomal unit → inhibiting protein synthesis

Antibiotic Sensitivities[2]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G I
Strep. Pneumoniae I
Viridans strep X1
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium R
MSSA I
MRSA R
CA-MRSA I
Staph. Epidermidis I
C. jeikeium R
L. monocytogenes S
Gram Negatives N. gonorrhoeae I
N. meningitidis X2
Moraxella catarrhalis I
H. influenzae I
E. coli R
Klebsiella sp R
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp X1
Serratia marcescens R
Salmonella sp R
Shigella sp R
Proteus mirabilis X1
Proteus vulgaris R
Providencia sp. X1
Morganella sp. X1
Citrobacter freundii X1
Citrobacter diversus X1
Citrobacter sp. X1
Aeromonas sp X1
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica R
Francisella tularensis X1
Brucella sp. R
Legionella sp. S
Pasteurella multocida X1
Haemophilus ducreyi S
Vibrio vulnificus X1
Misc Chlamydophila sp S
Mycoplasm pneumoniae S
Rickettsia sp I
Mycobacterium avium X1
Anaerobes Actinomyces S
Bacteroides fragilis R
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) I
Fusobacterium necrophorum R
Peptostreptococcus sp. I

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Pateron D, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011; 57(6):582-589.
  2. ↑ Sanford Guide to Antimicrobial Therapy 2014
Obtenido de «https://www.wikem.org/w/index.php?title=Erythromycin&oldid=386571»